Zembrace SymTouch (sumatriptan succinate) for Migraine

Overview
Zembrace SymTouch is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an acute (short-term) treatment for migraine in adults. Zembrace SymTouch is also referred to by its drug name, sumatriptan succinate.

Zembrace SymTouch is a selective 5-HT1B/1D receptor agonist. It works by binding to 5HT1B/1D receptors on blood vessels and nerves in the head. This action leads to constricting these blood vessels and interfering in the process of inflammation.

How do I take it?
Prescribing information states that Zembrace SymTouch is available as a 3-milligram subcutaneous (under the skin) injection that can be given up to four times a day.

Side effects
The FDA-approved label for Zembrace SymTouch lists common side effects including reactions at the injection site, numbness, burning sensation, feeling of heaviness, pressure sensation, warm/hot sensation, flushing, feeling of tightness, tingling, and dizziness/vertigo.

This medication is contraindicated (not recommended) for people with a history of coronary artery disease and a history of stroke.

For more details about this treatment, visit:

What Is Zembrace SymTouch — Upsher-Smith
https://www.zembrace.com/

Zembrace SymTouch — DailyMed
https://dailymed.nlm.nih.gov/dailymed/drugInfo....